SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Medical Radiology and Radiation Safety. 2015. Vol. 60. No. 5. P. 50-58

NUCLEAR MEDICINE

I.P. Aslanidis1, D.M.Pursanova1, O.V. Mukhortova1, A.V. Silchenkov1, O.B. Karyakin2, V.A. Biryukov2, V.I. Shirokorad3

Detection of Prostate Cancer Relapse with 11C-choline PET/CT in Patients after Radical Prostatectomy

1. A.N. Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; 2. A.F. Tsyb Medical Radiological Research Centre, Obninsk, Russia; 3. Moscow City Oncology Hospital No. 62, Moscow, Russia

ABSTRACT

Purpose: To evaluate the diagnostic impact of 11C-choline PET/CT in the detection of recurrent prostate cancer (PCa) in patients with biochemical relapse after radical prostatectomy and to assess the correlation between PSA levels and PET/CT detection rate of PCa relapse.

Methods and materials: 11C-choline PET/CT was performed in 58 patients (age range 50-79) with biochemical relapse after radical prostatectomy. Examinations were performed on PET/CT scanner (Biograph-64, Siemens) 10 min after injection of 11C-choline (700-950 MBq). The mean PSA value was 2.25 ± 2.87 (0.22-17.8) ng/ml. Patients were divided into three groups according to PSA level: ≤ 2 ng/ml, 2 to 9 ng/ml and ≥ 9 ng/ml.

Results: Overall, 11C-choline PET/CT detected PCa relapse in 18 of 58 patients (31 %). Positive PET/CT results were obtained in 8 of 39 patients (21 %) with PSA of ≤ 2 ng/ml, in 8 of 17 patients (47 %) with PSA of 2 to 9 ng/ml, and in 2 of 2 patients (100 %) with PSA of ≥ 9 ng/ml. Local relapse was detected in 55 % (10/18) patients. Both local and distant metastases were diagnosed in 28 % (5/18) cases: bone lesions (2), lymph nodes (2), lymph nodes and adrenal gland (1). Distant relapse was identified in 17 % (3/18) cases: bone (2) and lungs (1). PET/CT allowed to assess the efficacy of treatment in 25 % (10/40) PET-negative patients under hormone therapy at the scan time. However, PET/CT wasn’t able to localize the site of PCa recurrence in these hormone-sensitive patients what might have affected the overall detection rate.

Conclusion: 1) 11C-choline PET/CT was able to detect and correctly identify the site of PCa relapse in 46 % cases and therefore was useful in determining the further therapeutic approach. 2) Our data confirmed the strong correlation between PSA levels and 11C-choline PET/CT detection rate of PCa relapse (r = 0.9). 3) 11C-choline PET/CT has limited utility in localizing the site of PCa recurrence in some patients under hormone therapy.

Key words: prostate cancer recurrence, PET/CT, 11C-choline, PSA

REFERENCES

  1. Chissov V.I., Rusakov I.G. Zabolevaemost' rakom predstatel'noi zhelezy v Rossiiskoi Federatsii. Eksperim. i klin. urologiya. 2011. Vol. 3. No. 2. P. 6-7. (In Russ.).
  2. GLOBOCAN 2012 (IARC), Cancer Incidence and Mortality Worldwide, Section of Cancer Surveillance. Available from: http://globocan.iarc.fr/ (accessed: 21.03.2015).
  3. National Cancer Institute, Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Available from: http://seer.cancer.gov/statfacts/html/prost.html (accessed: 21.03.2015).
  4. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008. Vol. 58. No. 2. P. 71-96.
  5. Freedland S.J., Presti J.C. Jr., Amling C.L. et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urol. 2003. Vol. 61. P. 736-741.
  6. Han M., Partin A.W., Zahurak M. et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 2003. Vol. 169. P. 517-23.
  7. Reske S.N., Blumstein N.M., Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. No. 1. P. 9-17.
  8. National Collaborating Centre for Cancer. Managing relapse after radical treatment. In: Prostate cancer: diagnosis and treatment. NICE Ьinical Guidelines, Cardiff. 2008. No. 58. Ch. 5. P. 42-48.
  9. Cher M.L., Bianco F.J., Lam J.S. et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J. Urol. 1998. Vol. 160. No. 4. P. 1387-1391.
  10. Kane C.J., Amling C.L., Johnstone P.A. et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urol. 2003. Vol. 61. No. 3. P. 607-611.
  11. Olsson A.Y., Bjartell A., Lilja H., Lundwall A. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int. J. Cancer. 2005. Vol. 113. No. 2. P. 290-297.
  12. Partin A.W., Pearson J.D., Landis P.K. et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urol. 1994. Vol. 43. No. 5. P. 649-659.
  13. Dotan Z.A., Bianco F.J., Jr. et al. Pattern of prostatespecific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. JCO. 2005. Vol. 23. No. 9. P. 1962-1968.
  14. Apolo A.B., Pandit-Taskar N., Morris M.J. Novel tracers and their development for the imaging of metastatic prostate cancer. J. Nucl. Med. 2008. Vol. 49. P. 2031-2041.
  15. Kataja V.V., Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann. Oncol. 2005. Vol. 16. Suppl. 1. P. 34-36.
  16. Heidenreich A., Bastian P.J., Bellmunt J. et al. Guidelines on prostate cancer. European Association of Urology. Arnhem. 2012.
  17. Salomon C.G., Flisak M.E., Olson M.C. et al. Radical prostatectomy: transrectal sonographic evaluation to assess for local recurrence. Radiology. 1993. Vol. 189. No. 3. P. 713-719.
  18. Deliveliotis C., Manousakas T., Chrisofos M. et al. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA fol lowing radical prostatectomy. World J. Urol. 2007. Vol. 25. No. 3. P. 309-313.
  19. Beheshti M., Vali R., Waldenberger P. et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 1766-1774.
  20. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Eur. Urol. 2012. Vol. 61. P. 8-10.
  21. Aslanidi I.P., Pursanova D.M., Mukhortova O.V. et al. Rol' PET/KT s 11C-kholinom v rannei diagnostike progressirovaniya raka predstatel'noi zhelezy. Medical Radiology and Radiation Safety. 2014. Vol. 59. No. 5. P. 37-54.
  22. Rybalov M., Breeuwsma A.J., Leliveld A.M. et al. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-choline positron emission tomography in recurrent prostate cancer. World J. Urol. 2013. Vol. 31. No. 2. P. 319-323.
  23. Castellucci P., Fuccio C., Nanni C. et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J. Nucl. Med. 2009. Vol. 50. No. 9. P. 1394-400.
  24. Giovacchini G., Picchio M., Parra R.G. et al. Prostatespecific antigen velocity versus prostate specific antigen doubling time for prediction of 11C-choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin. Nucl. Med. 2012. Vol. 37. P. 325-331.
  25. Giovacchini G., Picchio M., Coradeschi E. et al. Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37. P. 301-309.
  26. Detti B., Scoccianti S., Franceschini D. et al. Predictive factors of [18F]-choline PET/CT in 170 patients with increasing PSA after primary radical treatment. J. Cancer Res. Oncol. 2013. Vol. 139. No. 3. P. 521-528.
  27. Krause B.J., Souvatzoglou M., Tuncel M. et al. The detection rate of [11C]choline PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 18-23.
  28. Schillaci O., Calabria F., Tavolozza M. et al. Influence of PSA, PSA velocity and PSA doublingtime on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging. 2012. Vol. 39. P. 589-596.
  29. Graute V., Jansen N., Ubleis C. et al. Relationship between PSA kinetics and [18F]fluoro-choline PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur. J. Nucl. Med. Mol. Imaging. 2012. Vol. 39. P. 271-282.
  30. Castellucci P., Fuccio C., Rubello D. et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38. P. 55-63.
  31. Dolgushin B., Odzharova A.A., Mikhailov A.I. et al. PET/KT s 18F-ftorkholinom v rezhime dvukhetapnogo skanirovaniya pri biokhimicheskikh retsi-divakh raka predstatel'noi zhelezy. Onkourologiya. 2015. Vol. 11. No. 2. P. 46-54. (In Russ.).
  32. Fuccio C., Schiavina R., Castellucci P. et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38. P. 1985-1989.
  33. Moul J.W. Prostate specific antigen only progression of prostate cancer. J. Urol. 2000. Vol. 163. P. 1632-1642.
  34. Roberts S.G., Blute M.L., Bergstralh E.J. et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin. Proc. 2001. Vol. 76. P. 576-581.
  35. Giovacchini G., Picchio M., Scattoni V. et al. PSA doubling time for prediction of 11C choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37. P. 1106-1116.

For citation: Aslanidis IP, Pursanova DM, Mukhortova OV, Silchenkov AV, Karyakin OB, Biryukov VA, Shirokorad VI. Detection of Prostate Cancer Relapse with 11C-choline PET/CT in Patients after Radical Prostatectomy. Medical Radiology and Radiation Safety. 2015;60(5):50-8. Russian.

PDF (RUS) Full-text article (in Russian)

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2764422
Today
Yesterday
This week
Last week
This month
Last month
For all time
316
4471
22806
18409
72165
75709
2764422

Your IP:216.73.216.37
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх